Safety Research Guide

Pregnancy and pediatrics, explained simply with PubMed links

This page translates Pregnancy and pediatrics research into plain English: what scientists studied, what kind of evidence exists, where the source links are strong or limited, and which PubMed records support each bucket.

Launch set page

Read Evidence Overview Open Source Table

106research sources

42evidence buckets

PubMedlinked references

What this page is

A plain-English research page about Pregnancy and pediatrics. It explains what researchers studied and links the PubMed or DOI sources.

How to use it

Read the overview first. If a sentence matters to you, open the PubMed link or source table below it.

Important limit

This page is education, not medical advice, dosing advice, or a recommendation to use cannabinoids.

Evidence Rows 129

Traceable statements carried into the source table.

Human Evidence 14

Rows where human participants, patients, or clinical evidence are visible.

Mechanisms 9

Biology, target, enzyme, receptor, or pharmacology rows.

Safety / Limits 27

Safety, tolerability, uncertainty, or insufficient-evidence context.

Evidence Overview

Pregnancy and pediatrics has research behind it, but the bucket matters.

This page currently indexes 106 research sources across 42 evidence bucket(s). Read it as a map of what researchers have studied, not as a single bottom-line instruction. PMID 33895189

Human evidence 14 evidence rows

Human studies are separated from preclinical and mechanistic evidence so a reader can see where people were actually studied. PMID 33895189

Mechanisms 9 evidence rows

Mechanistic rows explain biological plausibility, receptor activity, enzyme activity, or pharmacology; they do not automatically prove an outcome in people. PMID 33895189

Safety and limits 27 evidence rows

Safety, tolerability, product quality, impairment, interactions, and higher-risk contexts stay visible instead of being treated as footnotes. PMID 33895189

Evidence Buckets

What the Pregnancy and pediatrics research is usually about

Jump to source-backed table

Seizure and neurodevelopmental outcomes

Pregnancy and pediatrics appears in rows studying Seizure and neurodevelopmental outcomes. It currently draws from 21 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 33895189

Seizure and neurodevelopmental outcomes

Pregnancy and pediatrics appears in rows studying Seizure and neurodevelopmental outcomes. It currently draws from 18 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 36206805

pregnancy, lactation, pediatric, adolescent, or developmental contexts

Pregnancy and pediatrics appears in rows studying pregnancy, lactation, pediatric, adolescent, or developmental contexts. It currently draws from 13 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 35903331

pregnancy, lactation, pediatric, adolescent, or developmental contexts

Pregnancy and pediatrics appears in rows studying pregnancy, lactation, pediatric, adolescent, or developmental contexts. It currently draws from 9 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 37648266

pregnancy, lactation, pediatric, adolescent, or developmental contexts

Pregnancy and pediatrics appears in rows studying pregnancy, lactation, pediatric, adolescent, or developmental contexts. It currently draws from 8 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 40164212

Safety, risk, adverse events, and formulation concerns

Pregnancy and pediatrics appears in rows studying Safety, risk, adverse events, and formulation concerns. It currently draws from 5 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 37648266

Reader Map

Evidence buckets before the source table

Grouped for readability

Bucket	Plain-English meaning	Evidence posture	Starting source
Seizure and neurodevelopmental outcomes	Grouped source-backed rows focused on Seizure and neurodevelopmental outcomes, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (11), mechanistic or pharmacological (3), preclinical (5), preliminary human (2)	PMID 33895189
Seizure and neurodevelopmental outcomes	Grouped source-backed rows focused on Seizure and neurodevelopmental outcomes, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (14), mechanistic or pharmacological (1), preliminary human (3)	PMID 36206805
pregnancy, lactation, pediatric, adolescent, or developmental contexts	Grouped source-backed rows focused on pregnancy, lactation, pediatric, adolescent, or developmental contexts, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (11), preliminary human (2)	PMID 35903331
pregnancy, lactation, pediatric, adolescent, or developmental contexts	Grouped source-backed rows focused on pregnancy, lactation, pediatric, adolescent, or developmental contexts, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (7), preclinical (1), preliminary human (1)	PMID 37648266
pregnancy, lactation, pediatric, adolescent, or developmental contexts	Grouped source-backed rows focused on pregnancy, lactation, pediatric, adolescent, or developmental contexts, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (6), mechanistic or pharmacological (1), preliminary human (1)	PMID 40164212
Safety, risk, adverse events, and formulation concerns	Grouped source-backed rows focused on Safety, risk, adverse events, and formulation concerns, collapsed into one reader-facing bucket before the full source table.	Developed but mixed human research summary: insufficient (2), preliminary human (4)	PMID 37648266
drug-interaction mechanisms or safety-relevant outcomes	Grouped source-backed rows focused on drug-interaction mechanisms or safety-relevant outcomes, collapsed into one reader-facing bucket before the full source table.	Mapped evidence with interpretation limits: insufficient (4)	PMID 36206805
Psychiatric risk	Grouped source-backed rows focused on Psychiatric risk, collapsed into one reader-facing bucket before the full source table.	Mapped evidence with interpretation limits: insufficient (4)	PMID 41296368

Safety Reading Notes

Read safety context beside the research guide.

The Pregnancy and pediatrics source set includes safety-context rows around pregnancy, lactation, pediatric, adolescent, or developmental contexts. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 33895189

Developed but mixed human research summary: insufficient (11), preliminary human (2)

PubMed For Dummies Article

Pregnancy and pediatrics Evidence Review: the long-form source walk-through

Quick read

Pregnancy and pediatrics currently has 129 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 33895189
The evidence classes most visible in the row language are insufficient (91), preliminary human (20), mechanistic or pharmacological (10), and preclinical (8). PMID 36206805
The study-design language most visible in the row language is Narrative or expert review (56), Human clinical study (21), Systematic review (11), and other mapped categories (22). PMID 35156171
The repeated topics are Seizure and neurodevelopmental outcomes (39), pregnancy, lactation, pediatric, adolescent, or developmental contexts (30), safety, risk, adverse-event, or formulation-specific concerns (14), Pain-related outcomes (5), and other mapped categories (41), which tells the reader where to start opening PubMed and DOI links. PMID 35617670

Start with the research question

Pregnancy and pediatrics is built from 129 source-backed evidence row(s) and 106 research source(s). The current evidence classes read as insufficient (91), preliminary human (20), mechanistic or pharmacological (10), and preclinical (8), and the study-design language most often reads as Narrative or expert review (56), Human clinical study (21), Systematic review (11), and other mapped categories (22). PMID 33895189

The row-level question is not simply whether Pregnancy and pediatrics is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are Seizure and neurodevelopmental outcomes (39), pregnancy, lactation, pediatric, adolescent, or developmental contexts (30), safety, risk, adverse-event, or formulation-specific concerns (14), Pain-related outcomes (5), and other mapped categories (41). PMID 36206805

Human evidence 14 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 32335286

Preclinical evidence 8 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 32825313

Mechanistic evidence 9 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 36006807

Limits and uncertainty 118 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 39854828

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 41296368

Where this page has the most source density

The largest bucket surfaced for this page is Seizure and neurodevelopmental outcomes. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Seizure and neurodevelopmental outcomes, which gives readers another way to see what the literature repeatedly circles. PMID 33895189

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 36206805

Bucket chapters: what the literature is circling

Seizure and neurodevelopmental outcomes

21 research sources 21 rows (40-124) Developed but mixed human research summary: insufficient (11), mechanistic or pharmacological (3), preclinical (5), preliminary human (2)

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 33895189

Evidence row 40
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related o... PMID 33895189
Evidence row 124
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopm... PMID 41159452

Seizure and neurodevelopmental outcomes

18 research sources 18 rows (380-429) Developed but mixed human research summary: insufficient (14), mechanistic or pharmacological (1), preliminary human (3)

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 36206805

Evidence row 380
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis... PMID 36206805
Evidence row 429
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: s... PMID 33243685

pregnancy, lactation, pediatric, adolescent, or developmental contexts

13 research sources 13 rows (100-195) Developed but mixed human research summary: insufficient (11), preliminary human (2)

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 35903331

Evidence row 100
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrativ... PMID 35903331
Evidence row 195
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrativ... PMID 37330589

pregnancy, lactation, pediatric, adolescent, or developmental contexts

9 research sources 9 rows (98-194) Developed but mixed human research summary: insufficient (7), preclinical (1), preliminary human (1)

Evidence row 98
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review... PMID 37648266
Evidence row 194
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expe... PMID 33800053

pregnancy, lactation, pediatric, adolescent, or developmental contexts

8 research sources 8 rows (99-183) Developed but mixed human research summary: insufficient (6), mechanistic or pharmacological (1), preliminary human (1)

Evidence row 99
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expe... PMID 40164212
Evidence row 183
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy... PMID 38627667

Safety, risk, adverse events, and formulation concerns

5 research sources 6 rows (217-324) Developed but mixed human research summary: insufficient (2), preliminary human (4)

Evidence row 217
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome... PMID 37648266
Evidence row 324
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical stud... PMID 28538134

drug-interaction mechanisms or safety-relevant outcomes

4 research sources 4 rows (22-50) Mapped evidence with interpretation limits: insufficient (4)

This bucket groups source-backed rows where Pregnancy and pediatrics is interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes. It currently draws from 4 research source(s). PMID 36206805

Evidence row 22
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis... PMID 36206805
Evidence row 50
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; ou... PMID 39854828

Psychiatric risk

4 research sources 4 rows (434-438) Mapped evidence with interpretation limits: insufficient (4)

Pregnancy and pediatrics appears in rows studying Psychiatric risk. It currently draws from 4 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41296368

Evidence row 434
THC studied for Psychiatric risk; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes). PMID 41296368
Evidence row 438
THC studied for Psychiatric risk; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes). PMID 41801216

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (14 row(s)), mechanistic evidence (9 row(s)), and safety/tolerability context (27 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 33895189

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 36206805

What this does and does not mean

It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 41545891
It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 42339654
It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 33613289

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 33895189

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 36206805

Source-reading checklist for Pregnancy and pediatrics

Open the linked PubMed or DOI record. PMID 37641272
Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 37648266
Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 40164212
Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 35903331
Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 40589083

Source Notes

Pregnancy and pediatrics source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

Evidence row 22
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: drug-interaction or safety-relevant outcomes). PMID 36206805
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Evidence row 24
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: drug-interaction or safety-relevant outcomes). PMID 35156171
Evidence class: insufficient. Source: A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.
Evidence row 29
CBD studied for Anxiety-related outcomes; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes). PMID 35617670
Evidence class: preliminary human; Study design: Human clinical study. Source: Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial.
Evidence row 40
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 33895189
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder.
Evidence row 41
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 32335286
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol.
Evidence row 42
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 32825313
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies.
Evidence row 48
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Systematic review; outcome measure: drug-interaction or safety-relevant outcomes). PMID 36006807
Evidence class: insufficient; Study design: Systematic review. Source: Memantine for autism spectrum disorder.
Evidence row 50
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: drug-interaction or safety-relevant outcomes). PMID 39854828
Evidence class: insufficient; Study design: Narrative or expert review. Source: Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm.
Evidence row 58
CBD studied for Anxiety-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: anxiety-related outcomes). PMID 41296368
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
Evidence row 70
CBG studied for Pain-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 41545891
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
Evidence row 71
CBC studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes). PMID 41545891
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
Evidence row 84
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 42339654
Evidence class: insufficient; Study design: Narrative or expert review. Source: Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review.
Evidence row 85
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 33613289
Evidence class: insufficient; Study design: Narrative or expert review. Source: Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?
Evidence row 86
THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: preliminary human (study design: Human clinical study; outcome measure: safety, effect, or mechanism claims). PMID 37641272
Evidence class: preliminary human; Study design: Human clinical study. Source: Quality and safety of hemp meal as a protein supplement for nonlactating dairy cows.
Evidence row 98
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 37648266
Evidence class: insufficient; Study design: Systematic review. Source: Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.
Evidence row 99
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 40164212
Evidence class: insufficient; Study design: Narrative or expert review. Source: High Stakes: Exploring the Impact of Cannabis Use in Pregnancy and Lactation.
Evidence row 100
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 35903331
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding.
Evidence row 101
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 40589083
Evidence class: insufficient; Study design: Systematic review. Source: Risks of Cannabinoid Exposure on Birth Outcomes: A Systematic Review.
Evidence row 102
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 34035677
Evidence class: insufficient. Source: Management of Pediatric Cannabinoid Hyperemesis Syndrome: A Review.
Evidence row 103
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: mechanistic or pharmacological (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Human clinical study; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 39903192
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Effects of maternal edible THC consumption on offspring lung growth and function in a rhesus macaque model.
Evidence row 104
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 36730710
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Cannabis Use in Pregnancy and Neonatal Outcomes: A Systematic Review and Meta-Analysis.
Evidence row 105
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 37729034
Evidence class: preliminary human. Source: Variation in Hospital Practices Regarding Marijuana Use in Pregnancy and Lactation.
Evidence row 106
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 38469628
Evidence class: insufficient. Source: Association of Cannabis with Apneic Episodes in a Breastfed Infant: A Case Study.
Evidence row 109
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 29842819
Evidence class: insufficient; Study design: Narrative or expert review. Source: Investigational cannabinoids in seizure disorders, what have we learned thus far?
Evidence row 110
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 35364618
Evidence class: preclinical; Study design: Human clinical study. Source: Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial.
Evidence row 111
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 25475762
Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids and epilepsy.
Evidence row 112
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (outcome measure: seizure-related or neurodevelopmental outcomes). PMID 24282673
Evidence class: preclinical. Source: Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression.
Evidence row 113
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 29588939
Evidence class: preclinical. Source: Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin.
Evidence row 114
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 28799516
Evidence class: insufficient; Study design: Narrative or expert review. Source: Antiepileptic Drugs in Clinical Development: Differentiate or Die?
Evidence row 115
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 28845714
Evidence class: insufficient; Study design: Narrative or expert review. Source: The potential role of cannabinoids in epilepsy treatment.
Evidence row 116
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 30633929
Evidence class: preclinical; Study design: Animal study. Source: Preclinical safety and efficacy of cannabidivarin for early life seizures.
Evidence row 117
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 29214639
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids for epilepsy: What do we know and where do we go?
Evidence row 118
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 22970845
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidivarin is anticonvulsant in mouse and rat.
Evidence row 119
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 31447649
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats.
Evidence row 120
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 34210360
Evidence class: preliminary human; Study design: Human clinical study. Source: Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin.
Evidence row 121
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 36583706
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabidivarin alleviates α-synuclein aggregation via DAF-16 in Caenorhabditis elegans.
Evidence row 122
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 31748505
Evidence class: preliminary human; Study design: Human clinical study. Source: Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy.
Evidence row 123
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (study design: Systematic review; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 39541799
Evidence class: insufficient; Study design: Systematic review. Source: Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review.
Evidence row 124
CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes). PMID 41159452
Evidence class: preclinical; Study design: Animal study. Source: The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia.
Evidence row 125
CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes). PMID 41545891
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
Evidence row 155
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Case report or case series; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 36941718
Evidence class: preliminary human; Study design: Case report or case series. Source: Unintentional ingestion of putative delta-8 tetrahydrocannabinol by two youth requiring critical care: a case report.
Evidence row 158
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 11152013
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in clinical practice.
Evidence row 175
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 36206805
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Evidence row 176
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 41296368
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
Evidence row 177
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 28847562
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis use during pregnancy: Pharmacokinetics and effects on child development.
Evidence row 178
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 35662548
Evidence class: insufficient; Study design: Narrative or expert review. Source: Impact of cannabinoids on pregnancy, reproductive health, and offspring outcomes.
Evidence row 179
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 34021274
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis and synaptic reprogramming of the developing brain.
Evidence row 180
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 32943535
Evidence class: insufficient. Source: Long-term Cognitive, Psychological, and Health Outcomes Associated With Child Abuse and Neglect.
Evidence row 181
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 25439854
Evidence class: insufficient; Study design: Narrative or expert review. Source: [Consequences of tobacco, cocaine and cannabis consumption during pregnancy on the pregnancy itself, on the newborn and on child development: A review].
Evidence row 182
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 37651516
Evidence class: insufficient. Source: Smoke Alarm.
Evidence row 183
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 38627667
Evidence class: preliminary human. Source: Development and validation of the Cannabis Exposure in Pregnancy Tool (CEPT): a mixed methods study.
Evidence row 184
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 40353977
Evidence class: insufficient. Source: Maternal cannabis use in pregnancy, perinatal outcomes, and cognitive development in offspring: a longitudinal analysis of the ALSPAC cohort using paternal cannabis use as a negative control exposure.
Evidence row 185
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 40121379
Evidence class: insufficient. Source: Longitudinal Associations Between Cannabis Use during Pregnancy and Child Cognitive, Motor, and Language Development at 2 Years Old.
Evidence row 186
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 26724101
Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Evidence row 187
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 25479151
Evidence class: preliminary human; Study design: Human clinical study. Source: Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.
Evidence row 188
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Systematic review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 33754312
Evidence class: insufficient; Study design: Systematic review. Source: Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Evidence row 189
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 42057496
Evidence class: insufficient; Study design: Narrative or expert review. Source: An Overview of Cannabinoid Interactions With Common Pediatric Antineoplastic Agents.
Evidence row 190
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 32661188
Evidence class: insufficient; Study design: Narrative or expert review. Source: Marijuana and the Pediatric Population.
Evidence row 191
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preclinical (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Animal study; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 41840986
Evidence class: preclinical; Study design: Animal study. Source: Oral Consumption of Cannabidiol During Pregnancy Alters Behavior in Mouse Offspring.
Evidence row 192
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 27139708
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pediatric Concerns Due to Expanded Cannabis Use: Unintended Consequences of Legalization.
Evidence row 193
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 41683846
Evidence class: insufficient; Study design: Narrative or expert review. Source: Recreational Cannabis Use During Human Pregnancy: Its Effects on the Placenta and Endocannabinoid System.
Evidence row 194
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 33800053
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Signalling in Immune-Reproductive Crosstalk during Human Pregnancy.
Evidence row 195
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts). PMID 37330589
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis for morning sickness: areas for intervention to decrease cannabis consumption during pregnancy.
Evidence row 197
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 39585547
Evidence class: insufficient; Study design: Narrative or expert review. Source: Update on Cannabidiol in Drug-Resistant Epilepsy.
Evidence row 199
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 33667843
Evidence class: insufficient. Source: Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.
Evidence row 200
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 37593907
Evidence class: insufficient. Source: Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program.
Evidence row 217
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 37648266
Evidence class: insufficient; Study design: Systematic review. Source: Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.
Evidence row 220
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 20562767
Evidence class: insufficient. Source: Cannabis and psychiatric disorders.
Evidence row 227
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 42204954
Evidence class: preliminary human; Study design: Human clinical study. Source: A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability.
Evidence row 234
Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and nausea/vomiting research outcomes). PMID 36791365
Evidence class: insufficient; Study design: Narrative or expert review. Source: Diagnosis and Management of Cyclic Vomiting Syndrome: A Critical Review.
Evidence row 238
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 33897066
Evidence class: preliminary human; Study design: Human clinical study. Source: Adverse Effects of Recreational and Medical Cannabis.
Evidence row 239
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 30771373
Evidence class: insufficient; Study design: Narrative or expert review. Source: Prenatal cannabinoid exposure and altered neurotransmission.
Evidence row 252
THC studied for Rare phytocannabinoids research topics; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: Rare phytocannabinoids research topics). PMID 38940871
Evidence class: insufficient. Source: A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol.
Evidence row 269
THC studied for Cannabinoids and immune modulation research outcomes; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes). PMID 36746342
Evidence class: preclinical; Study design: Animal study. Source: Maternal immune activation impairs endocannabinoid signaling in the mesolimbic system of adolescent male offspring.
Evidence row 273
THC studied for Cannabinoids and immune modulation research outcomes; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and immune modulation research outcomes). PMID 12648025
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacokinetics and pharmacodynamics of cannabinoids.
Evidence row 280
CBD studied for receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 34384142
Evidence class: preclinical; Study design: Animal study. Source: Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.
Evidence row 311
THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 32829065
Evidence class: preliminary human. Source: Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta.
Evidence row 320
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 37648266
Evidence class: insufficient; Study design: Systematic review. Source: Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.
Evidence row 321
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 26724101
Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Evidence row 323
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 29768152
Evidence class: preliminary human; Study design: Human clinical study. Source: Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Evidence row 324
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 28538134
Evidence class: preliminary human; Study design: Human clinical study. Source: Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Evidence row 325
THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 38940871
Evidence class: insufficient. Source: A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol.
Evidence row 335
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Cellular or in vitro study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 36710464
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Delta-8 tetrahydrocannabinol: a scoping review and commentary.
Evidence row 345
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 36439142
Evidence class: insufficient; Study design: Narrative or expert review. Source: Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations.
Evidence row 349
Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 38686923
Evidence class: insufficient. Source: Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America's Poison Centers.
Evidence row 365
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 29768152
Evidence class: preliminary human; Study design: Human clinical study. Source: Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Evidence row 370
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 40774642
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Evaluating cannabidiol-induced liver injury with and without valproate using a three-dimensional human hepatocyte spheroid model.
Evidence row 374
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 29678279
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Psychiatric Consequences of Cannabinoids.
Evidence row 380
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: seizure-related outcomes). PMID 36206805
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Evidence row 383
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Systematic review; outcome measure: seizure-related outcomes). PMID 33754312
Evidence class: insufficient; Study design: Systematic review. Source: Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Evidence row 384
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes). PMID 33332006
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
Evidence row 385
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: seizure-related outcomes). PMID 36417631
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
Evidence row 386
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes). PMID 36194365
Evidence class: insufficient; Study design: Narrative or expert review. Source: Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.
Evidence row 390
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes). PMID 38731471
Evidence class: insufficient; Study design: Narrative or expert review. Source: CBD in the Treatment of Epilepsy.
Evidence row 391
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes). PMID 37655228
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies.
Evidence row 415
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes). PMID 39854828
Evidence class: insufficient; Study design: Narrative or expert review. Source: Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm.
Evidence row 416
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes). PMID 26724101
Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Evidence row 419
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes). PMID 29768152
Evidence class: preliminary human; Study design: Human clinical study. Source: Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Evidence row 420
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes). PMID 28538134
Evidence class: preliminary human; Study design: Human clinical study. Source: Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Evidence row 421
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: seizure-related outcomes). PMID 40836583
Evidence class: insufficient; Study design: Narrative or expert review. Source: State-of-the-art management of Dravet syndrome.
Evidence row 422
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes). PMID 29540584
Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
Evidence row 423
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: seizure-related outcomes). PMID 37695433
Evidence class: insufficient; Study design: Systematic review. Source: Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Evidence row 424
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes). PMID 40072476
Evidence class: insufficient; Study design: Human clinical study. Source: Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome.
Evidence row 426
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes). PMID 40468679
Evidence class: insufficient; Study design: Narrative or expert review. Source: Current and emerging pharmacotherapies in Lennox-Gastaut syndrome.
Evidence row 427
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: seizure-related outcomes). PMID 33825230
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Anti-seizure medications for Lennox-Gastaut syndrome.
Evidence row 429
CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes). PMID 33243685
Evidence class: insufficient; Study design: Narrative or expert review. Source: Management of Lennox-Gastaut syndrome beyond childhood: A comprehensive review.
Evidence row 430
CBD studied for Pain-related outcomes; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: pain-related outcomes). PMID 37648266
Evidence class: insufficient; Study design: Systematic review. Source: Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.
Evidence row 434
THC studied for Psychiatric risk; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes). PMID 41296368
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
Evidence row 435
THC studied for Psychiatric risk; evidence class: insufficient (study design: Systematic review; outcome measure: psychiatric risk outcomes). PMID 39541799
Evidence class: insufficient; Study design: Systematic review. Source: Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review.
Evidence row 437
THC studied for Psychiatric risk; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes). PMID 39299947
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits.
Evidence row 438
THC studied for Psychiatric risk; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes). PMID 41801216
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis and Mental Health: A Review.
Evidence row 471
THC studied for Pain-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 41296368
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
Evidence row 478
THC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 29307505
Evidence class: insufficient; Study design: Narrative or expert review. Source: Practical considerations in medical cannabis administration and dosing.
Evidence row 480
THC studied for Nausea and vomiting; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes). PMID 41296368
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Use of Cannabis and Cannabinoids: A Review.
Evidence row 483
THC studied for Nausea and vomiting; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes). PMID 39299947
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits.
Evidence row 505
THC studied for Sleep; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes). PMID 33215831
Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabis: are there any benefits?
Evidence row 514
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns). PMID 27428345
Evidence class: insufficient; Study design: Narrative or expert review. Source: [Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences].
Evidence row 518
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 36424484
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish.
Evidence row 535
CBN studied for Pain-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: pain-related outcomes). PMID 36424484
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish.
Evidence row 543
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 11152013
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in clinical practice.
Evidence row 556
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42107483
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The impact of cannabigerol exposure on human endometrial stromal cells decidualization.
Evidence row 673
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 33395525
Evidence class: insufficient; Study design: Animal study. Source: Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome.
Evidence row 714
CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 35354487
Evidence class: insufficient. Source: Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: part 1 - continuous bivariate analysis.
Evidence row 757
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 36280497
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies.
Evidence row 790
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 28109780
Evidence class: insufficient; Study design: Narrative or expert review. Source: Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy.
Evidence row 915
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 40332343
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Inflammatory Bowel Disease.
Evidence row 1069
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 20302856
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoids and pregnancy.
Evidence row 1111
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 28215162
Evidence class: insufficient; Study design: Narrative or expert review. Source: Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases.
Evidence row 1170
DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms). PMID 27759003
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Orphan GPR110 (ADGRF1) targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function.

Source Trail

Source-backed evidence table and references

106 research sources

This section is the technical source layer under the overview. It keeps grouped evidence buckets, evidence rows, PubMed or DOI links, related pages, and references visible for audit and revision.

Plain-Language Summary

This safety page summarizes source-backed cannabinoid evidence about Pregnancy and pediatrics. It contains 129 evidence row(s); wording should stay descriptive and avoid instructions.

Identity

Canonical name: pregnancy-pediatrics
Type: safety topic
Subtype: Not recorded
Description: Heightened-review population topic; not eligible for autonomous publication.

Evidence Snapshot

Evidence rows: 129
Sources: 106
Evidence classes: insufficient (91), mechanistic or pharmacological (10), preclinical (8), preliminary human (20)
Draft sections: human evidence (14), mechanistic evidence (9), preclinical evidence (8), safety (27), uncertainty (71)

Key Draft Sections

Human evidence: 14 evidence row(s).
Safety and tolerability: 27 evidence row(s).
Uncertainty and gaps: 71 evidence row(s).
Preclinical evidence: 8 evidence row(s).
Mechanistic evidence: 9 evidence row(s).

Safety Evidence By Compound Or Product

Subject	Relationship	Object Or Focus	Evidence Summary	Sources	Evidence Rows
Anandamide	studied for	anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms	Mapped evidence with interpretation limits: insufficient (1)	1	1069
Cannabinoids	studied for	Cannabinoids and nausea/vomiting research outcomes	Mapped evidence with interpretation limits: insufficient (1)	1	234
Cannabinoids	modulates	CB2	Mechanistic research summary: mechanistic or pharmacological (1)	1	915
Cannabinoids	studied for	pregnancy, lactation, pediatric, adolescent, or developmental contexts	Developed but mixed human research summary: insufficient (11), preliminary human (2)	13	13 rows (100-195)
Cannabinoids	studied for	safety, risk, adverse-event, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (3)	3	3 rows (220-374)
CBC	studied for	Inflammation-related outcomes	Mapped evidence with interpretation limits: insufficient (1)	1	71
CBC	modulates	receptor, transporter, target, metabolic, or pharmacology mechanisms	Mapped evidence with interpretation limits: insufficient (1)	1	673
CBC	studied for	Skin and inflammatory dermatology	Mapped evidence with interpretation limits: insufficient (1)	1	714
CBD	studied for	Anxiety-related outcomes	Early human research summary: insufficient (1), preliminary human (1)	2	2 rows (29-58)
CBD	interacts with drug or class	drug-interaction mechanisms or safety-relevant outcomes	Mapped evidence with interpretation limits: insufficient (4)	4	4 rows (22-50)
CBD	modulates	endocannabinoid enzyme activity or metabolic mechanisms	Early human research summary: mechanistic or pharmacological (1), preliminary human (1)	2	2 rows (365-370)
CBD	studied for	Pain-related outcomes	Mapped evidence with interpretation limits: insufficient (1)	1	430
CBD	studied for	pregnancy, lactation, pediatric, adolescent, or developmental contexts	Developed but mixed human research summary: insufficient (7), preclinical (1), preliminary human (1)	9	9 rows (98-194)
CBD	studied for	receptor, target, or pharmacology mechanisms	Preclinical research summary: preclinical (1)	1	280
CBD	studied for	safety, adverse-event, impairment, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (3)	3	3 rows (197-200)
CBD	studied for	safety, risk, adverse-event, or formulation-specific concerns	Developed but mixed human research summary: insufficient (2), preliminary human (4)	5	6 rows (217-324)
CBD	studied for	Seizure and neurodevelopmental outcomes	Developed but mixed human research summary: insufficient (14), mechanistic or pharmacological (1), preliminary human (3)	18	18 rows (380-429)
CBDA	studied for	nausea-related or inflammation-related outcomes	Mapped evidence with interpretation limits: insufficient (1)	1	125
CBDV	studied for	Seizure and neurodevelopmental outcomes	Developed but mixed human research summary: insufficient (11), mechanistic or pharmacological (3), preclinical (5), preliminary human (2)	21	21 rows (40-124)
CBG	studied for	Pain-related outcomes	Mapped evidence with interpretation limits: insufficient (1)	1	70
CBG	studied for	safety, adverse-event, impairment, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (1)	1	158
CBG	studied for	safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)	2	2 rows (543-556)
CBN	studied for	Pain-related outcomes	Mapped evidence with interpretation limits: insufficient (1)	1	535
CBN	modulates	receptor, target, metabolic, or pharmacology mechanisms	Mechanistic research summary: mechanistic or pharmacological (1)	1	518
CBN	studied for	safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (1)	1	514
Delta-8 THC	studied for	safety, adverse-event, impairment, or formulation-specific concerns	Early human research summary: preliminary human (1)	1	155
Delta-8 THC	studied for	safety, risk, adverse-event, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (335-349)
DHEA / synaptamide	studied for	DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms	Mechanistic research summary: mechanistic or pharmacological (1)	1	1170
Endocannabinoids	studied for	safety, risk, adverse-event, or formulation-specific concerns	Early human research summary: insufficient (1), preliminary human (1)	2	2 rows (238-345)
PEA	studied for	PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms	Mapped evidence with interpretation limits: insufficient (1)	1	1111
THC	studied for	Cannabinoids and immune modulation research outcomes	Preclinical research summary: insufficient (1), preclinical (1)	2	2 rows (269-273)
THC	modulates	endocannabinoid enzyme activity or metabolic mechanisms	Early human research summary: preliminary human (1)	1	311
THC	studied for	Nausea and vomiting	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (480-483)
THC	studied for	Pain-related outcomes	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (471-478)
THC	studied for	pregnancy, lactation, pediatric, adolescent, or developmental contexts	Developed but mixed human research summary: insufficient (6), mechanistic or pharmacological (1), preliminary human (1)	8	8 rows (99-183)
THC	studied for	Psychiatric risk	Mapped evidence with interpretation limits: insufficient (4)	4	4 rows (434-438)
THC	studied for	Rare phytocannabinoids research topics	Mapped evidence with interpretation limits: insufficient (1)	1	252
THC	studied for	safety, risk, adverse-event, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (1)	1	325
THC	studied for	Sleep	Early human research summary: preliminary human (1)	1	505
THCA	studied for	THCA-specific safety, effect, or mechanism claims	Early human research summary: preliminary human (1)	1	86
THCV	studied for	neurobehavioral, cognition, mood, reward, or THC-interaction outcomes	Mapped evidence with interpretation limits: insufficient (1)	1	790
THCV	studied for	safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (1)	1	757

Source-Backed Evidence Table

Evidence Row	Statement	Source
22	CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: drug-interaction or safety-relevant outcomes).	Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.PubMed 36206805 DOI 10.1016/j.expneurol.2022.114238
24	CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: drug-interaction or safety-relevant outcomes).	A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.PubMed 35156171 DOI 10.1007/s40263-022-00898-1
29	CBD studied for Anxiety-related outcomes; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: anxiety-related outcomes).	Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial.PubMed 35617670 DOI 10.47626/2237-6089-2021-0396
40	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes).	Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder.PubMed 33895189 DOI 10.1016/j.pharmthera.2021.107878
41	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes).	Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol.PubMed 32335286 DOI 10.1016/j.phrs.2020.104822
42	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes).	Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies.PubMed 32825313 DOI 10.3390/brainsci10090572
48	CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Systematic review; outcome measure: drug-interaction or safety-relevant outcomes).	Memantine for autism spectrum disorder.PubMed 36006807 DOI 10.1002/14651858.cd013845.pub2
50	CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: drug-interaction or safety-relevant outcomes).	Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm.PubMed 39854828 DOI 10.1016/j.yebeh.2024.110261
58	CBD studied for Anxiety-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: anxiety-related outcomes).	Therapeutic Use of Cannabis and Cannabinoids: A Review.PubMed 41296368 DOI 10.1001/jama.2025.19433
70	CBG studied for Pain-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes).	Therapeutic potential of acidic cannabinoids: an update.PubMed 41545891 DOI 10.1186/s42238-026-00387-y
71	CBC studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes).	Therapeutic potential of acidic cannabinoids: an update.PubMed 41545891 DOI 10.1186/s42238-026-00387-y
84	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes).	Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review.PubMed 42339654 DOI 10.1177/10445463261462382
85	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes).	Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?PubMed 33613289 DOI 10.3389/fphar.2020.635763
86	THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: preliminary human (study design: Human clinical study; outcome measure: safety, effect, or mechanism claims).	Quality and safety of hemp meal as a protein supplement for nonlactating dairy cows.PubMed 37641272 DOI 10.3168/jds.2023-23222
98	CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.PubMed 37648266 DOI 10.1136/bmj-2022-072348
99	THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	High Stakes: Exploring the Impact of Cannabis Use in Pregnancy and Lactation.PubMed 40164212 DOI 10.1542/neo.26-4-006
100	Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding.PubMed 35903331 DOI 10.3389/fphar.2022.919630
101	THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Risks of Cannabinoid Exposure on Birth Outcomes: A Systematic Review.PubMed 40589083 DOI 10.1089/can.2025.0027
102	Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Management of Pediatric Cannabinoid Hyperemesis Syndrome: A Review.PubMed 34035677 DOI 10.5863/1551-6776-26.4.339
103	THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: mechanistic or pharmacological (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Human clinical study; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Effects of maternal edible THC consumption on offspring lung growth and function in a rhesus macaque model.PubMed 39903192 DOI 10.1152/ajplung.00360.2024
104	Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Cannabis Use in Pregnancy and Neonatal Outcomes: A Systematic Review and Meta-Analysis.PubMed 36730710 DOI 10.1089/can.2022.0262
105	Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Variation in Hospital Practices Regarding Marijuana Use in Pregnancy and Lactation.PubMed 37729034 DOI 10.1089/bfm.2023.0138
106	THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Association of Cannabis with Apneic Episodes in a Breastfed Infant: A Case Study.PubMed 38469628 DOI 10.1089/bfm.2024.0047
109	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes).	Investigational cannabinoids in seizure disorders, what have we learned thus far?PubMed 29842819 DOI 10.1080/13543784.2018.1482275
110	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related or neurodevelopmental outcomes).	Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial.PubMed 35364618 DOI 10.1111/epi.17247
111	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes).	Phytocannabinoids and epilepsy.PubMed 25475762 DOI 10.1111/jcpt.12235
112	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (outcome measure: seizure-related or neurodevelopmental outcomes).	Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression.PubMed 24282673 DOI 10.7717/peerj.214
113	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; outcome measure: seizure-related or neurodevelopmental outcomes).	Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin.PubMed 29588939 DOI 10.1002/epi4.12015
114	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes).	Antiepileptic Drugs in Clinical Development: Differentiate or Die?PubMed 28799516 DOI 10.2174/1381612823666170809100524
115	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes).	The potential role of cannabinoids in epilepsy treatment.PubMed 28845714 DOI 10.1080/14737175.2017.1373019
116	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes).	Preclinical safety and efficacy of cannabidivarin for early life seizures.PubMed 30633929 DOI 10.1016/j.neuropharm.2019.01.002
117	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related or neurodevelopmental outcomes).	Cannabinoids for epilepsy: What do we know and where do we go?PubMed 29214639 DOI 10.1111/epi.13973
118	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes).	Cannabidivarin is anticonvulsant in mouse and rat.PubMed 22970845 DOI 10.1111/j.1476-5381.2012.02207.x
119	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes).	Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats.PubMed 31447649 DOI 10.3389/fncel.2019.00367
120	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: seizure-related or neurodevelopmental outcomes).	Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin.PubMed 34210360 DOI 10.1186/s13229-021-00454-6
121	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: seizure-related or neurodevelopmental outcomes).	Cannabidivarin alleviates α-synuclein aggregation via DAF-16 in Caenorhabditis elegans.PubMed 36583706 DOI 10.1096/fj.202200278rr
122	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: seizure-related or neurodevelopmental outcomes).	Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy.PubMed 31748505 DOI 10.1038/s41398-019-0654-8
123	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (study design: Systematic review; outcome measure: seizure-related or neurodevelopmental outcomes).	Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review.PubMed 39541799 DOI 10.1016/j.euroneuro.2024.10.006
124	CBDV studied for Seizure and neurodevelopmental outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: seizure-related or neurodevelopmental outcomes).	The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia.PubMed 41159452 DOI 10.1177/02698811251381246
125	CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes).	Therapeutic potential of acidic cannabinoids: an update.PubMed 41545891 DOI 10.1186/s42238-026-00387-y
155	Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Case report or case series; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	Unintentional ingestion of putative delta-8 tetrahydrocannabinol by two youth requiring critical care: a case report.PubMed 36941718 DOI 10.1186/s42238-023-00176-x
158	CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	Cannabinoids in clinical practice.PubMed 11152013 DOI 10.2165/00003495-200060060-00005
175	CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.PubMed 36206805 DOI 10.1016/j.expneurol.2022.114238
176	CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Therapeutic Use of Cannabis and Cannabinoids: A Review.PubMed 41296368 DOI 10.1001/jama.2025.19433
177	THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Cannabis use during pregnancy: Pharmacokinetics and effects on child development.PubMed 28847562 DOI 10.1016/j.pharmthera.2017.08.014
178	THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Impact of cannabinoids on pregnancy, reproductive health, and offspring outcomes.PubMed 35662548 DOI 10.1016/j.ajog.2022.05.056
179	THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Cannabis and synaptic reprogramming of the developing brain.PubMed 34021274 DOI 10.1038/s41583-021-00465-5
180	Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Long-term Cognitive, Psychological, and Health Outcomes Associated With Child Abuse and Neglect.PubMed 32943535 DOI 10.1542/peds.2020-0438
181	Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	[Consequences of tobacco, cocaine and cannabis consumption during pregnancy on the pregnancy itself, on the newborn and on child development: A review].PubMed 25439854 DOI 10.1016/j.encep.2014.08.012
182	Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Smoke Alarm.PubMed 37651516 DOI 10.1126/science.adk5505
183	THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Development and validation of the Cannabis Exposure in Pregnancy Tool (CEPT): a mixed methods study.PubMed 38627667 DOI 10.1186/s12884-024-06485-0
184	Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Maternal cannabis use in pregnancy, perinatal outcomes, and cognitive development in offspring: a longitudinal analysis of the ALSPAC cohort using paternal cannabis use as a negative control exposure.PubMed 40353977 DOI 10.1007/s10654-025-01233-w
185	Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Longitudinal Associations Between Cannabis Use during Pregnancy and Child Cognitive, Motor, and Language Development at 2 Years Old.PubMed 40121379 DOI 10.1007/s10995-025-04077-8
186	CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.PubMed 26724101 DOI 10.1016/s1474-4422(15
187	Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.PubMed 25479151 DOI 10.1155/2014/754693
188	CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Systematic review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.PubMed 33754312 DOI 10.1007/s40263-021-00807-y
189	Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	An Overview of Cannabinoid Interactions With Common Pediatric Antineoplastic Agents.PubMed 42057496 DOI 10.1002/1545-5017.70336
190	Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Marijuana and the Pediatric Population.PubMed 32661188 DOI 10.1542/peds.2019-2629
191	CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: preclinical (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Animal study; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Oral Consumption of Cannabidiol During Pregnancy Alters Behavior in Mouse Offspring.PubMed 41840986 DOI 10.1177/25785125251413416
192	CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Pediatric Concerns Due to Expanded Cannabis Use: Unintended Consequences of Legalization.PubMed 27139708 DOI 10.1007/s13181-016-0552-x
193	CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Recreational Cannabis Use During Human Pregnancy: Its Effects on the Placenta and Endocannabinoid System.PubMed 41683846 DOI 10.3390/ijms27031398
194	CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Cannabinoid Signalling in Immune-Reproductive Crosstalk during Human Pregnancy.PubMed 33800053 DOI 10.3390/biomedicines9030267
195	Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: pregnancy, lactation, pediatric, adolescent, or developmental contexts).	Cannabis for morning sickness: areas for intervention to decrease cannabis consumption during pregnancy.PubMed 37330589 DOI 10.1186/s42238-023-00184-x
197	CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	Update on Cannabidiol in Drug-Resistant Epilepsy.PubMed 39585547 DOI 10.1007/s12098-024-05337-1
199	CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.PubMed 33667843 DOI 10.1016/j.yebeh.2021.107862
200	CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program.PubMed 37593907 DOI 10.1002/epi4.12815
217	CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.PubMed 37648266 DOI 10.1136/bmj-2022-072348
220	Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Cannabis and psychiatric disorders.PubMed 20562767
227	CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability.PubMed 42204954 DOI 10.1177/10445463261452514
234	Cannabinoids studied for Cannabinoids and nausea/vomiting research outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and nausea/vomiting research outcomes).	Diagnosis and Management of Cyclic Vomiting Syndrome: A Critical Review.PubMed 36791365 DOI 10.14309/ajg.0000000000002216
238	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Adverse Effects of Recreational and Medical Cannabis.PubMed 33897066 DOI 10.64719/pb.4395
239	Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Prenatal cannabinoid exposure and altered neurotransmission.PubMed 30771373 DOI 10.1016/j.neuropharm.2019.02.018
252	THC studied for Rare phytocannabinoids research topics; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: Rare phytocannabinoids research topics).	A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol.PubMed 38940871 DOI 10.1007/s00216-024-05396-5
269	THC studied for Cannabinoids and immune modulation research outcomes; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes).	Maternal immune activation impairs endocannabinoid signaling in the mesolimbic system of adolescent male offspring.PubMed 36746342 DOI 10.1016/j.bbi.2023.02.002
273	THC studied for Cannabinoids and immune modulation research outcomes; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and immune modulation research outcomes).	Pharmacokinetics and pharmacodynamics of cannabinoids.PubMed 12648025 DOI 10.2165/00003088-200342040-00003
280	CBD studied for receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.PubMed 34384142 DOI 10.1111/bph.15661
311	THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Pregnancy, lactation, or reproductive context mentioned; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta.PubMed 32829065 DOI 10.1016/j.bbalip.2020.158807
320	CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.PubMed 37648266 DOI 10.1136/bmj-2022-072348
321	CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.PubMed 26724101 DOI 10.1016/s1474-4422(15
323	CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.PubMed 29768152 DOI 10.1056/nejmoa1714631
324	CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.PubMed 28538134 DOI 10.1056/nejmoa1611618
325	THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol.PubMed 38940871 DOI 10.1007/s00216-024-05396-5
335	Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Cellular or in vitro study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Delta-8 tetrahydrocannabinol: a scoping review and commentary.PubMed 36710464 DOI 10.1111/add.16142
345	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations.PubMed 36439142 DOI 10.3389/fimmu.2022.1029818
349	Delta-8 THC studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America's Poison Centers.PubMed 38686923 DOI 10.1080/15563650.2024.2340115
365	CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.PubMed 29768152 DOI 10.1056/nejmoa1714631
370	CBD modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Evaluating cannabidiol-induced liver injury with and without valproate using a three-dimensional human hepatocyte spheroid model.PubMed 40774642 DOI 10.1016/j.tiv.2025.106126
374	Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	The Psychiatric Consequences of Cannabinoids.PubMed 29678279 DOI 10.1016/j.clinthera.2018.03.013
380	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: seizure-related outcomes).	Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.PubMed 36206805 DOI 10.1016/j.expneurol.2022.114238
383	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Systematic review; outcome measure: seizure-related outcomes).	Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.PubMed 33754312 DOI 10.1007/s40263-021-00807-y
384	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes).	Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.PubMed 33332006 DOI 10.1007/978-3-030-57369-0_7
385	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: seizure-related outcomes).	Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.PubMed 36417631 DOI 10.1590/1806-9282.2022d689
386	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes).	Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.PubMed 36194365 DOI 10.1007/s40263-022-00955-9
390	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes).	CBD in the Treatment of Epilepsy.PubMed 38731471 DOI 10.3390/molecules29091981
391	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes).	Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies.PubMed 37655228 DOI 10.1177/17562864231191000
415	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes).	Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm.PubMed 39854828 DOI 10.1016/j.yebeh.2024.110261
416	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes).	Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.PubMed 26724101 DOI 10.1016/s1474-4422(15
419	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes).	Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.PubMed 29768152 DOI 10.1056/nejmoa1714631
420	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes).	Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.PubMed 28538134 DOI 10.1056/nejmoa1611618
421	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: seizure-related outcomes).	State-of-the-art management of Dravet syndrome.PubMed 40836583 DOI 10.1111/dmcn.16475
422	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: mechanistic or pharmacological (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes).	Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.PubMed 29540584 DOI 10.1212/wnl.0000000000005254
423	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: seizure-related outcomes).	Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.PubMed 37695433 DOI 10.1007/s40265-023-01936-y
424	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: seizure-related outcomes).	Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome.PubMed 40072476 DOI 10.1111/epi.18342
426	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes).	Current and emerging pharmacotherapies in Lennox-Gastaut syndrome.PubMed 40468679 DOI 10.1080/14656566.2025.2516630
427	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: seizure-related outcomes).	Anti-seizure medications for Lennox-Gastaut syndrome.PubMed 33825230 DOI 10.1002/14651858.cd003277.pub4
429	CBD studied for Seizure and neurodevelopmental outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: seizure-related outcomes).	Management of Lennox-Gastaut syndrome beyond childhood: A comprehensive review.PubMed 33243685 DOI 10.1016/j.yebeh.2020.107612
430	CBD studied for Pain-related outcomes; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Systematic review; outcome measure: pain-related outcomes).	Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.PubMed 37648266 DOI 10.1136/bmj-2022-072348
434	THC studied for Psychiatric risk; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes).	Therapeutic Use of Cannabis and Cannabinoids: A Review.PubMed 41296368 DOI 10.1001/jama.2025.19433
435	THC studied for Psychiatric risk; evidence class: insufficient (study design: Systematic review; outcome measure: psychiatric risk outcomes).	Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review.PubMed 39541799 DOI 10.1016/j.euroneuro.2024.10.006
437	THC studied for Psychiatric risk; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes).	Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits.PubMed 39299947 DOI 10.1007/s00406-024-01880-2
438	THC studied for Psychiatric risk; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes).	Cannabis and Mental Health: A Review.PubMed 41801216 DOI 10.1001/jamainternmed.2025.8215
471	THC studied for Pain-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes).	Therapeutic Use of Cannabis and Cannabinoids: A Review.PubMed 41296368 DOI 10.1001/jama.2025.19433
478	THC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes).	Practical considerations in medical cannabis administration and dosing.PubMed 29307505 DOI 10.1016/j.ejim.2018.01.004
480	THC studied for Nausea and vomiting; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes).	Therapeutic Use of Cannabis and Cannabinoids: A Review.PubMed 41296368 DOI 10.1001/jama.2025.19433
483	THC studied for Nausea and vomiting; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: nausea, vomiting, or antiemetic outcomes).	Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits.PubMed 39299947 DOI 10.1007/s00406-024-01880-2
505	THC studied for Sleep; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: sleep-related outcomes).	Cannabis: are there any benefits?PubMed 33215831 DOI 10.1111/imj.15052
514	CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns).	[Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences].PubMed 27428345
518	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish.PubMed 36424484 DOI 10.1038/s41598-022-23495-0
535	CBN studied for Pain-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: pain-related outcomes).	Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish.PubMed 36424484 DOI 10.1038/s41598-022-23495-0
543	CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Cannabinoids in clinical practice.PubMed 11152013 DOI 10.2165/00003495-200060060-00005
556	CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	The impact of cannabigerol exposure on human endometrial stromal cells decidualization.PubMed 42107483 DOI 10.1016/j.tox.2026.154492
673	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome.PubMed 33395525 DOI 10.1021/acschemneuro.0c00677
714	CBC studied for Skin and inflammatory dermatology; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: part 1 - continuous bivariate analysis.PubMed 35354487 DOI 10.1186/s13690-022-00811-8
757	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies.PubMed 36280497 DOI 10.1016/j.tem.2022.08.003
790	THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes).	Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy.PubMed 28109780 DOI 10.1016/j.yebeh.2016.11.020
915	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Inflammatory Bowel Disease.PubMed 40332343 DOI 10.3390/ijms26083720
1069	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Pregnancy, lactation, or reproductive context mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Endocannabinoids and pregnancy.PubMed 20302856 DOI 10.1016/j.cca.2010.03.012
1111	PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms).	Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases.PubMed 28215162 DOI 10.2174/0929867324666170216113756
1170	DHEA / synaptamide studied for DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: DHEA/synaptamide biology, receptor or signaling mechanisms, metabolism, physiology, or safety-relevant mechanisms).	Orphan GPR110 (ADGRF1) targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function.PubMed 27759003 DOI 10.1038/ncomms13123

Anandamide
Anxiety-related outcomes
CB2
CBC
CBD
CBDA
CBDV
CBG
CBN
Cannabinoids
DHEA / synaptamide
Delta-8 THC
Endocannabinoids
Inflammation-related outcomes
Nausea and vomiting
PEA
Pain-related outcomes
Psychiatric risk
Seizure and neurodevelopmental outcomes
Skin and inflammatory dermatology

References

Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.PubMed 36206805 DOI 10.1016/j.expneurol.2022.114238
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.PubMed 35156171 DOI 10.1007/s40263-022-00898-1
Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial.PubMed 35617670 DOI 10.47626/2237-6089-2021-0396
Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder.PubMed 33895189 DOI 10.1016/j.pharmthera.2021.107878
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol.PubMed 32335286 DOI 10.1016/j.phrs.2020.104822
Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies.PubMed 32825313 DOI 10.3390/brainsci10090572
Memantine for autism spectrum disorder.PubMed 36006807 DOI 10.1002/14651858.cd013845.pub2
Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm.PubMed 39854828 DOI 10.1016/j.yebeh.2024.110261
Therapeutic Use of Cannabis and Cannabinoids: A Review.PubMed 41296368 DOI 10.1001/jama.2025.19433
Therapeutic potential of acidic cannabinoids: an update.PubMed 41545891 DOI 10.1186/s42238-026-00387-y
Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review.PubMed 42339654 DOI 10.1177/10445463261462382
Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?PubMed 33613289 DOI 10.3389/fphar.2020.635763
Quality and safety of hemp meal as a protein supplement for nonlactating dairy cows.PubMed 37641272 DOI 10.3168/jds.2023-23222
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.PubMed 37648266 DOI 10.1136/bmj-2022-072348
High Stakes: Exploring the Impact of Cannabis Use in Pregnancy and Lactation.PubMed 40164212 DOI 10.1542/neo.26-4-006
Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding.PubMed 35903331 DOI 10.3389/fphar.2022.919630
Risks of Cannabinoid Exposure on Birth Outcomes: A Systematic Review.PubMed 40589083 DOI 10.1089/can.2025.0027
Management of Pediatric Cannabinoid Hyperemesis Syndrome: A Review.PubMed 34035677 DOI 10.5863/1551-6776-26.4.339
Effects of maternal edible THC consumption on offspring lung growth and function in a rhesus macaque model.PubMed 39903192 DOI 10.1152/ajplung.00360.2024
Cannabis Use in Pregnancy and Neonatal Outcomes: A Systematic Review and Meta-Analysis.PubMed 36730710 DOI 10.1089/can.2022.0262
Variation in Hospital Practices Regarding Marijuana Use in Pregnancy and Lactation.PubMed 37729034 DOI 10.1089/bfm.2023.0138
Association of Cannabis with Apneic Episodes in a Breastfed Infant: A Case Study.PubMed 38469628 DOI 10.1089/bfm.2024.0047
Investigational cannabinoids in seizure disorders, what have we learned thus far?PubMed 29842819 DOI 10.1080/13543784.2018.1482275
Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial.PubMed 35364618 DOI 10.1111/epi.17247
Phytocannabinoids and epilepsy.PubMed 25475762 DOI 10.1111/jcpt.12235
Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression.PubMed 24282673 DOI 10.7717/peerj.214
Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin.PubMed 29588939 DOI 10.1002/epi4.12015
Antiepileptic Drugs in Clinical Development: Differentiate or Die?PubMed 28799516 DOI 10.2174/1381612823666170809100524
The potential role of cannabinoids in epilepsy treatment.PubMed 28845714 DOI 10.1080/14737175.2017.1373019
Preclinical safety and efficacy of cannabidivarin for early life seizures.PubMed 30633929 DOI 10.1016/j.neuropharm.2019.01.002
Cannabinoids for epilepsy: What do we know and where do we go?PubMed 29214639 DOI 10.1111/epi.13973
Cannabidivarin is anticonvulsant in mouse and rat.PubMed 22970845 DOI 10.1111/j.1476-5381.2012.02207.x
Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats.PubMed 31447649 DOI 10.3389/fncel.2019.00367
Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin.PubMed 34210360 DOI 10.1186/s13229-021-00454-6
Cannabidivarin alleviates α-synuclein aggregation via DAF-16 in Caenorhabditis elegans.PubMed 36583706 DOI 10.1096/fj.202200278rr
Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy.PubMed 31748505 DOI 10.1038/s41398-019-0654-8
Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review.PubMed 39541799 DOI 10.1016/j.euroneuro.2024.10.006
The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia.PubMed 41159452 DOI 10.1177/02698811251381246
Unintentional ingestion of putative delta-8 tetrahydrocannabinol by two youth requiring critical care: a case report.PubMed 36941718 DOI 10.1186/s42238-023-00176-x
Cannabinoids in clinical practice.PubMed 11152013 DOI 10.2165/00003495-200060060-00005
Cannabis use during pregnancy: Pharmacokinetics and effects on child development.PubMed 28847562 DOI 10.1016/j.pharmthera.2017.08.014
Impact of cannabinoids on pregnancy, reproductive health, and offspring outcomes.PubMed 35662548 DOI 10.1016/j.ajog.2022.05.056
Cannabis and synaptic reprogramming of the developing brain.PubMed 34021274 DOI 10.1038/s41583-021-00465-5
Long-term Cognitive, Psychological, and Health Outcomes Associated With Child Abuse and Neglect.PubMed 32943535 DOI 10.1542/peds.2020-0438
[Consequences of tobacco, cocaine and cannabis consumption during pregnancy on the pregnancy itself, on the newborn and on child development: A review].PubMed 25439854 DOI 10.1016/j.encep.2014.08.012
Smoke Alarm.PubMed 37651516 DOI 10.1126/science.adk5505
Development and validation of the Cannabis Exposure in Pregnancy Tool (CEPT): a mixed methods study.PubMed 38627667 DOI 10.1186/s12884-024-06485-0
Maternal cannabis use in pregnancy, perinatal outcomes, and cognitive development in offspring: a longitudinal analysis of the ALSPAC cohort using paternal cannabis use as a negative control exposure.PubMed 40353977 DOI 10.1007/s10654-025-01233-w
Longitudinal Associations Between Cannabis Use during Pregnancy and Child Cognitive, Motor, and Language Development at 2 Years Old.PubMed 40121379 DOI 10.1007/s10995-025-04077-8
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.PubMed 26724101 DOI 10.1016/s1474-4422(15
Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.PubMed 25479151 DOI 10.1155/2014/754693
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.PubMed 33754312 DOI 10.1007/s40263-021-00807-y
An Overview of Cannabinoid Interactions With Common Pediatric Antineoplastic Agents.PubMed 42057496 DOI 10.1002/1545-5017.70336
Marijuana and the Pediatric Population.PubMed 32661188 DOI 10.1542/peds.2019-2629
Oral Consumption of Cannabidiol During Pregnancy Alters Behavior in Mouse Offspring.PubMed 41840986 DOI 10.1177/25785125251413416
Pediatric Concerns Due to Expanded Cannabis Use: Unintended Consequences of Legalization.PubMed 27139708 DOI 10.1007/s13181-016-0552-x
Recreational Cannabis Use During Human Pregnancy: Its Effects on the Placenta and Endocannabinoid System.PubMed 41683846 DOI 10.3390/ijms27031398
Cannabinoid Signalling in Immune-Reproductive Crosstalk during Human Pregnancy.PubMed 33800053 DOI 10.3390/biomedicines9030267
Cannabis for morning sickness: areas for intervention to decrease cannabis consumption during pregnancy.PubMed 37330589 DOI 10.1186/s42238-023-00184-x
Update on Cannabidiol in Drug-Resistant Epilepsy.PubMed 39585547 DOI 10.1007/s12098-024-05337-1
Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.PubMed 33667843 DOI 10.1016/j.yebeh.2021.107862
Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program.PubMed 37593907 DOI 10.1002/epi4.12815
Cannabis and psychiatric disorders.PubMed 20562767
A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability.PubMed 42204954 DOI 10.1177/10445463261452514
Diagnosis and Management of Cyclic Vomiting Syndrome: A Critical Review.PubMed 36791365 DOI 10.14309/ajg.0000000000002216
Adverse Effects of Recreational and Medical Cannabis.PubMed 33897066 DOI 10.64719/pb.4395
Prenatal cannabinoid exposure and altered neurotransmission.PubMed 30771373 DOI 10.1016/j.neuropharm.2019.02.018
A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol.PubMed 38940871 DOI 10.1007/s00216-024-05396-5
Maternal immune activation impairs endocannabinoid signaling in the mesolimbic system of adolescent male offspring.PubMed 36746342 DOI 10.1016/j.bbi.2023.02.002
Pharmacokinetics and pharmacodynamics of cannabinoids.PubMed 12648025 DOI 10.2165/00003088-200342040-00003
Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.PubMed 34384142 DOI 10.1111/bph.15661
Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta.PubMed 32829065 DOI 10.1016/j.bbalip.2020.158807
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.PubMed 29768152 DOI 10.1056/nejmoa1714631
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.PubMed 28538134 DOI 10.1056/nejmoa1611618
Delta-8 tetrahydrocannabinol: a scoping review and commentary.PubMed 36710464 DOI 10.1111/add.16142
Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations.PubMed 36439142 DOI 10.3389/fimmu.2022.1029818
Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America's Poison Centers.PubMed 38686923 DOI 10.1080/15563650.2024.2340115
Evaluating cannabidiol-induced liver injury with and without valproate using a three-dimensional human hepatocyte spheroid model.PubMed 40774642 DOI 10.1016/j.tiv.2025.106126
The Psychiatric Consequences of Cannabinoids.PubMed 29678279 DOI 10.1016/j.clinthera.2018.03.013
Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.PubMed 33332006 DOI 10.1007/978-3-030-57369-0_7
Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.PubMed 36417631 DOI 10.1590/1806-9282.2022d689
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.PubMed 36194365 DOI 10.1007/s40263-022-00955-9
CBD in the Treatment of Epilepsy.PubMed 38731471 DOI 10.3390/molecules29091981
Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies.PubMed 37655228 DOI 10.1177/17562864231191000
State-of-the-art management of Dravet syndrome.PubMed 40836583 DOI 10.1111/dmcn.16475
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.PubMed 29540584 DOI 10.1212/wnl.0000000000005254
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.PubMed 37695433 DOI 10.1007/s40265-023-01936-y
Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome.PubMed 40072476 DOI 10.1111/epi.18342
Current and emerging pharmacotherapies in Lennox-Gastaut syndrome.PubMed 40468679 DOI 10.1080/14656566.2025.2516630
Anti-seizure medications for Lennox-Gastaut syndrome.PubMed 33825230 DOI 10.1002/14651858.cd003277.pub4
Management of Lennox-Gastaut syndrome beyond childhood: A comprehensive review.PubMed 33243685 DOI 10.1016/j.yebeh.2020.107612
Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits.PubMed 39299947 DOI 10.1007/s00406-024-01880-2
Cannabis and Mental Health: A Review.PubMed 41801216 DOI 10.1001/jamainternmed.2025.8215
Practical considerations in medical cannabis administration and dosing.PubMed 29307505 DOI 10.1016/j.ejim.2018.01.004
Cannabis: are there any benefits?PubMed 33215831 DOI 10.1111/imj.15052
[Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences].PubMed 27428345
Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish.PubMed 36424484 DOI 10.1038/s41598-022-23495-0
The impact of cannabigerol exposure on human endometrial stromal cells decidualization.PubMed 42107483 DOI 10.1016/j.tox.2026.154492
Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome.PubMed 33395525 DOI 10.1021/acschemneuro.0c00677
Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: part 1 - continuous bivariate analysis.PubMed 35354487 DOI 10.1186/s13690-022-00811-8
Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies.PubMed 36280497 DOI 10.1016/j.tem.2022.08.003
Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy.PubMed 28109780 DOI 10.1016/j.yebeh.2016.11.020
Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Inflammatory Bowel Disease.PubMed 40332343 DOI 10.3390/ijms26083720
Endocannabinoids and pregnancy.PubMed 20302856 DOI 10.1016/j.cca.2010.03.012
Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases.PubMed 28215162 DOI 10.2174/0929867324666170216113756
Orphan GPR110 (ADGRF1) targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function.PubMed 27759003 DOI 10.1038/ncomms13123

Pregnancy and pediatrics has research behind it, but the bucket matters.

What the Pregnancy and pediatrics research is usually about

Seizure and neurodevelopmental outcomes

Seizure and neurodevelopmental outcomes

pregnancy, lactation, pediatric, adolescent, or developmental contexts

pregnancy, lactation, pediatric, adolescent, or developmental contexts

pregnancy, lactation, pediatric, adolescent, or developmental contexts

Safety, risk, adverse events, and formulation concerns

Evidence buckets before the source table

Keep reading around this topic

Read safety context beside the research guide.

Pregnancy and pediatrics Evidence Review: the long-form source walk-through

Start with the research question

Where this page has the most source density

Bucket chapters: what the literature is circling

Seizure and neurodevelopmental outcomes

Seizure and neurodevelopmental outcomes

pregnancy, lactation, pediatric, adolescent, or developmental contexts

pregnancy, lactation, pediatric, adolescent, or developmental contexts

pregnancy, lactation, pediatric, adolescent, or developmental contexts

Safety, risk, adverse events, and formulation concerns

drug-interaction mechanisms or safety-relevant outcomes

Psychiatric risk

Human evidence, mechanisms, and safety are different lanes

What this does and does not mean

How to use the source table

Source-reading checklist for Pregnancy and pediatrics

Pregnancy and pediatrics source-by-source reading notes

Source-backed evidence table and references

Plain-Language Summary

Identity

Evidence Snapshot

Key Draft Sections

Safety Evidence By Compound Or Product

Source-Backed Evidence Table

Related Pages

References